1 The Role of X Chromosome in Alzheimer's Disease Genetics.

Authors: Michael E. Belloy^{1-3,*}, PhD, Yann Le Guen^{1,4,*}, PhD, Ilaria Stewart¹, BA, Joachim Herz⁵, MD, Richard
 Sherva⁶, PhD, Rui Zhang⁷, MS, Victoria Merritt^{8,9}, PhD, Matthew S. Panizzon^{9,10}, PhD, Richard L. Hauger^{8,9,10},
 MD, the VA Million Veteran Program, J. Michael Gaziano^{11,12}, MD, Mark Logue^{6,7,13,14}, PhD, Valerio

5 Napolioni^{15,#}, PhD, and Michael D. Greicius^{1,#}, MD MPH.

- 5 Napolioni^{15,#}, PhD, and Michael D. Greicius^{1,#}, MD MPH.
 6
- 7 ¹Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA
- 8 ²NeuroGenomics and Informatics Center, Washington University School of Medicine, St.Louis, MO, USA
- ³Department of Neurology, Washington University School of Medicine, St.Louis, MO, USA
- 10 ⁴Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
- ⁵Center for Translational Neurodegeneration Research, Department of Molecular Genetics University of Texas
- 12 Southwestern Medical Center at Dallas, Dallas, TX, USA
- 13 ⁶Biomedical Genetics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
- ¹⁴ ⁷National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, MA, USA
- 15 ⁸Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA
- ⁹Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
- 17 ¹⁰Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA, USA
- 18 ¹¹Million Veteran Program (MVP) Coordinating Center, VA Boston Healthcare System, Boston, MA, USA
- 19 ¹²Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
- 20 ¹³Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
- 21 ¹⁴Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
- ¹⁵School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
 23
- 24 *Equal contribution; #Equal contribution
- 25

26 Corresponding Author

- 27 Michael E. Belloy
- 28 Department of Neurology
- 29 NeuroGenomics and Informatics Center (NGI)
- 30 Washington University in Saint Louis (WashU)
- 31 4444 Forest Park Ave, St. Louis, MO 63108, USA
- 32 Phone: (+1) 314-747-2608
- 33 Email: <u>belloy@wustl.edu</u>

34 Key points

- 35 Question: Does the X chromosome play a role in the genetics of Alzheimer's Disease (AD)?
- 36 Findings: In a genetic meta-analysis across 1,152,284 individuals, several X chromosome loci were
- 37 associated with AD. Four loci showed evidence of shared genetic associations between AD risk and
- regulation of nearby gene expression in brain tissue. The top association signal was intronic on *SLC9A7*
- 39 and linked to its expression.
- 40 Meaning: We performed the first large-scale X chromosome-wide association study of AD and prioritized
- 41 *SLC9A7* as a novel risk locus. This study significantly advances our knowledge of AD genetics and provides
- 42 novel biological drug targets.

43 Abstract

44 Importance: The X chromosome has remained enigmatic in Alzheimer's disease (AD), yet it makes up 5%

- 45 of the genome and carries a high proportion of genes expressed in the brain, making it particularly
- 46 appealing as a potential source of unexplored genetic variation in AD.
- 47 Objectives: Perform the first large-scale X chromosome-wide association study (XWAS) of AD. Primary
 48 analyses are non-stratified, while secondary analyses evaluate sex-stratified effects.
- 49 Design: Meta-analysis of genetic association studies in case-control, family-based, population-based, and
 50 longitudinal AD-related cohorts from the US Alzheimer's Disease Genetics Consortium (ADGC) and
- 51 Alzheimer's Disease Sequencing Project (ADSP), the UK Biobank (UKB), the Finnish health registry
- 52 (FinnGen), and the US Million Veterans Program (MVP). Risk for AD evaluated through case-control logistic
- regression analyses. Data were analyzed between January 2023 and March 2024.
- Setting: Genetic data available from high-density single-nucleotide polymorphism (SNP) microarrays and
 whole-genome sequencing (WGS). Summary statistics for multi-tissue expression and protein quantitative
 trait loci (QTL) available from published studies, enabling follow-up genetic colocalization analyses.
- 57 Participants: 1,629,863 eligible participants were selected from referred and volunteer samples, of which
 58 477,596 were excluded for analysis exclusion criteria. Number of participants who declined to participate
 59 in original studies was not available.
- Main Outcome and Measures: Risk for AD (odds ratio; OR) with 95% confidence intervals (CI).
 Associations were considered at X-chromosome-wide (P-value<1e-5) and genome-wide (P-value<5e-8)
 significance.
- Results: Analyses included 1,152,284 non-Hispanic White European ancestry subjects (57.3% females),
 including 138,558 cases. 6 independent genetic loci passed X-chromosome-wide significance, with 4
 showing support for causal links between the genetic signal for AD and expression of nearby genes in
 brain and non-brain tissues. One of these 4 loci passed conservative genome-wide significance, with its
 lead variant centered on an intron of *SLC9A7* (OR=1.054, 95%-CI=[1.035, 1.075]) and colocalization
 analyses prioritizing both the *SLC9A7* and nearby *CHST7* genes.
- 69 Conclusion and Relevance: We performed the first large-scale XWAS of AD and identified the novel
 70 SLC9A7 locus. SLC9A7 regulates pH homeostasis in Golgi secretory compartments and is anticipated to

- 71 have downstream effects on amyloid beta accumulation. Overall, this study significantly advances our
- 72 knowledge of AD genetics and may provide novel biological drug targets.

73 Introduction

74 The X chromosome has remained enigmatic, not just in AD, but in the broader field of genome-wide 75 association studies. It is typically excluded due to technical challenges and power limitations because of 76 its complex inheritance pattern¹. The X chromosome however makes up 5% of the genome and carries a 77 high proportion of genes expressed in the brain. Additionally, it may contribute to the well-established 78 higher prevalence of AD in women relative to men². We thus set out to fill in this gap by performing the 79 first meta-analysis of XWAS conducted on various publicly available AD-related cohorts, as well as multiple 80 biobanks where AD phenotypes were available. To ensure maximal power, this study was designed as a 81 large-scale discovery combining all available samples.

82 Methods

An in-depth overview of all methodologies is provided in the **eMethods**. The current study followed STREGA reporting guidelines. Participants or their caregivers provided written informed consent in the original studies. The current study protocol was granted an exemption by the Stanford Institutional Review Board because the analyses were carried out on "de-identified, off-the-shelf" data; therefore, additional informed consent was not required.

88 Data Ascertainment

Case-control, family-based, and longitudinal AD genetic cohorts from the ADGC and ADSP (release-3) were available through public repositories, with genetic data from SNP microarrays and WGS (eTable1-2)^{3,4}. These cohorts contributed clinically diagnosed AD cases (40.0% pathology verified; eTable3). Analyses in UKB, FinnGen, and MVP used genetic data from SNP microarrays^{5–8}. UKB data and FinnGen summary results (v10) were publicly available. UKB contributed health-registry-confirmed AD cases and proxy Alzheimer's disease-and-dementia (ADD) cases; FinnGen contributed health-registry-confirmed AD cases.

96 Quality Control and Processing

ADGC and ADSP data underwent extensive quality control (QC) and imputation to the TOPMed
 reference panel (eTable4-5). Specific consideration was given to X-chromosome QC as in prior work (cf.
 eMethods)⁹. Genetic data processing for UKB, FinnGen, and MVP followed cohort-specific protocols^{5–8}.
 Non-Hispanic White, European ancestry cases and controls, carrying XX or XY with concordant self reported sex and ages >60 years (>18 and median=63 in FinnGen), were retained for analyses (eFigure1;
 eTable3). Variants were filtered using cohort-specific minor allele frequency (MAF) criteria, which on
 average correspond to MAF>0.05% (eTable5).

104 X chromosome Considerations

105 X chromosome analyses considered non-pseudoautosomal regions. Genotype encoding was 0/2 in men 106 (XY) and 0/1/2 in women (XX), following a random X chromosome inactivation (XCI) model in women. In 107 UKB, most cases were proxy cases, i.e. family history of ADD in first-degree relatives. This proxy approach 108 has been established to replicate AD autosomal genetic risk factors and be adaptable to XWAS¹⁰. To 109 maximize power, the health-registry and proxy status were unified into a single phenotype for which

association coefficients were adjusted onto a regular case-control scale (eTable6-7). After rescaling, UKB
 showed consistent coefficient distributions with ADGC+ADSP (eFigure2). A similar approach was used in
 MVP, but in line with MVP protocols, analyses were separated for health-registry and proxy phenotypes⁷.

113 Statistical Analyses

114 XWAS evaluated case-control logistic regressions on AD risk, adjusting for sex, age, technical covariates, and genetic principal components (capturing population stratification) as applicable per dataset. Mixed 115 models to include related subjects were used in ADGC, ADSP, UKB (LMM-BOLT v2.4)¹¹, and FinnGen 116 (Regenie)⁶. Association results across datasets were combined through fixed effects inverse-variance 117 118 weighted meta-analyses. Primary analyses were non-stratified. Secondary analyses were sex-stratified, 119 and conducted across ADGC, ADSP, and UKB. Association results were considered at the X-chromosome-120 wide (P-value<1e-5) and conservative genome-wide thresholds (P-value<5e-8). Sex effects were 121 evaluated through heterogeneity tests and considered significant at P<0.05. Evidence for escape from XCI 122 was evaluated by comparing variant beta coefficients derived from men and women-stratified XWAS (ratio=1 indicates escape; ratio=2 indicates no escape)¹². 123

124 Genetic Colocalization

To identify potentially causal genes in associated risk loci, statistical colocalization was evaluated between the local genetic association signal for AD and the genetic association signal for molecular traits such as expression levels of genes within that locus (R-v.4.2.1, *coloc*)¹³. We leveraged public datasets where quantitative trait loci (QTL) for expression and protein levels were available for the X chromosome in brain and non-brain tissues (cf. **eMethods**).

130 Results

131 The study design is provided in Figure1A. 1,152,284 individuals (138,558 cases: 15,081 clinically 132 diagnosed cases, 41,091 health-registry-confirmed cases, and 82,386 proxy cases) were included in the XWAS (eTable3). There was no sign of genomic inflation (eFigure3). We associated 2 rare (MAF<1%) lead 133 134 variants in the NLGN4X and MID1 loci, and 4 common lead variants in the SLC9A7, ZNF280C, ARGRG4, and 135 MTM1 loci (Table1; locus zoom and forest plots in eFigures4-5). All common variant loci showed 136 colocalization for at least one nearby gene in brain tissue (Table2; eTable8). The overall top association 137 signal (cross-cohort allele frequencies in eTable9), intronic on SLC9A7, passed conservative significance 138 criteria and showed colocalization for several genes, most notably SLC9A7 and CHST7. Colocalization plots 139 for top prioritized genes are in eFigures6-10.

The *ZNF280C* and *ARGRG4* lead variants showed evidence for escape from XCI, while the *MID1* variant appeared female-specific (**eTable10**). Sex-stratified XWAS only revealed 1 X-chromosome-wide significant, female-specific rare variant association without colocalization support (**eFigure11**, **eTable11**) and indicated that evidence for escape from XCI was apparent only for a few common, small effect size variants (**eFigure12**).

145 Discussion

We performed an XWAS of AD in 1.152,284 individuals, making this the largest genetic association 146 147 study of AD to date¹⁴. The top signal showed support for a causal link between the genetic regulation of SLC9A7 or CHST7 expression and AD risk. CHST7 encodes a chondroitin 6-sulfotransferase that confers 148 149 negatively charged sulfate groups to glycosaminoglycans, which may relate to promoting tau fibrillization 150 and spreading¹⁵. Notably, *SLC9A7* (a.k.a *NHE7*) is a paralog of *SLC9A6* (a.k.a *NHE6*), previously implicated in experimental work as an X-linked AD modifying gene¹⁶. These are highly conserved genes that regulate 151 152 pH homeostasis in Golgi secretory compartments and endosomes and might thus be expected to 153 contribute to increased amyloid accumulation across aging when their expression levels are increased (a 154 detailed background and rationale are provided in Appendix-A). In line with this expectation, QTL data 155 support that the top risk allele is associated with increased expression of SLC9A7 in brain tissue, increasing 156 expression by 17-44% for an active allele (eTable12). Although the SLC9A7 top variant has a small effect size (OR=1.054, 95%-CI=[1.035, 1.075]), given this relatively small effect on SLC9A7 expression in the brain, 157 158 it may be that more substantial reduction or pharmacological inhibition of SLC9A7 would prove to be an 159 effective therapeutic strategy for AD.

160 Despite this study's formidable sample size, only the SLC9A7 locus reached conservative significance 161 criteria with a small effect size, suggesting the X chromosome contributes relatively little to AD prevalence. In addition, only 2 lead variants of small effect size indicated escape from XCI and only 1 rare 162 163 lead variant appeared female-specific, such that these XWAS results have little bearing on sex-stratified 164 AD prevalence. Similarly, sex-stratified XWAS did not reveal striking results, which would have been 165 expected if the X chromosome played a significant role in the observations that 2/3 of AD patients across 166 the lifespan are women². Overall, our results suggest that while the X chromosome plays only a small role 167 in the population prevalence of AD, the specific pathways highlighted here open the door to novel 168 pathogenic pathways and associated drug targets.

169 Limitations

This study focused on European ancestry individuals. When larger cross-ancestry samples become available, future studies should extend AD XWAS into these populations. Similarly, future, larger sexstratified AD XWAS may help identify sex-specific risk genes and genes escaping from XCI. Lastly, this study did not provide conclusive insight into the causal gene at the *SLC9A7* locus, which future experimental studies should interrogate.

175 Conclusion

- 176 We performed the first large-scale XWAS of AD and identified the novel *SLC9A7* risk locus. Overall, this
- 177 study significantly advances our knowledge of the genetics of AD and may provide novel biological drug
- 178 targets.

179 Consent for publication

180 Not applicable.

181 Availability of data and materials

- 182 Data used in the XWAS are available upon application to:
- 183 dbGaP (<u>https://www.ncbi.nlm.nih.gov/gap/</u>)
- 184 NIAGADS (https://www.niagads.org/)
- 185 LONI (<u>https://ida.loni.usc.edu/</u>)
- 186 AMP-AD knowledge portal / Synapse (https://www.synapse.org/)
- 187 Rush (<u>https://www.radc.rush.edu/</u>)
- 188 NACC (<u>https://naccdata.org/</u>)
- 189 UKB (https://www.ukbiobank.ac.uk/)
- 190 FinnGen (<u>https://www.finngen.fi/en</u>)
- 191 MVP (<u>https://www.mvp.va.gov/</u>)

192 The specific data repository and identifier for ADGC and ADSP data are indicated in **eTable1** of the 193 supplement.

194 The data, code, and phenotypes used to generate MVP results are accessible to researchers with MVP

data access. Due to VA policy, MVP is currently only accessible to VA researchers with a funded MVP

196 project, either through a VA Merit Award, career development award, or NIH R01. Additional information

197 is available at <u>https://genhub.va.gov/file/view/897656</u>. GWAS summary results for the MVP cohort will

198 be posted to dbGAP after publication.

199 Colocalization datasets are available from:

- 200 AMP-AD knowledge portal / Synapse (<u>https://www.synapse.org/</u>; identifier: syn51150434)
- 201 eQTL catalogue (<u>https://www.ebi.ac.uk/eqtl/</u>)
- 202 GTEx (<u>https://www.gtexportal.org/home/</u>)
- 203 <u>Summary statistics generated by this study will be deposited in both NIAGADS and the EMBL-EBI GWAS</u>
 204 <u>Catalog.</u>

205 Competing/Conflicting interests

206 The authors declare no competing or conflicting interests.

207 Funding/Support

- 208 Funding for this study was provided by the NIH (R00AG075238, M.E.B; AG060747 and AG047366, M.D.G)
- and the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-
- 210 Curie (grant agreement No. 890650, Y.L.G.). JH was supported by grants from the NIH (NS108115), the
- Alzheimer's Association (ABA-22-970304) and the Kleberg Foundation. This study included data from the
- 212 Million Veteran Program, Office of Research and Development, Veterans Health Administration. MVP data
- analyses were supported by VA BLR&D grants BX004192 (MVP015; PI Logue) and BX005749 (MVP040; PI
- Logue). Dr. Richard Hauger was supported by MVP022 award CX001727, VISN-22 VA Center of Excellence
- for Stress and Mental Health (CESAMH), and National Institute of Aging R01 grants AG050595.

216 Role of Funder/Sponsor

- 217 The funding organizations and sponsors had no role in the design and conduct of the study; collection,
- 218 management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript;
- and decision to submit the manuscript for publication.

220 Authors' contributions

221 M.E.B., Y.L. and M.D.G. had full access to all the data in the study and take responsibility for the integrity 222 of the data and the accuracy of the data analysis. M.E.B. performed data acquisition and analyses, 223 designed analyses, designed study, wrote paper, and obtained funding. Y.L. performed data acquisition 224 and analyses, designed analyses, designed study, and wrote paper. I.S. performed data acquisition and 225 analyses. J.H. co-wrote the paper. M.W.L. and J.M.G were involved in data, funding, and resource 226 acquisition. M.W.L, R.S., V.M., M.S.P., and R.L.H. were involved in conceptualization and study design. R.Z. 227 and R.S. analyzed and curated data. V.N. performed data acquisition and analyses, designed study, 228 designed analyses, supervised analyses, and supervised work. M.D.G designed study, designed analyses, 229 supervised analyses, supervised work, wrote paper, and obtained funding. All authors contributed to 230 critical revision of the manuscript.

231 Acknowledgements

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's
Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the
National Institute on Aging. The contents of this article do not represent the views of the National
Institutes of Health, the U.S. Department of Veterans Affairs, or the United States Government.

236 Acknowledgments for the use of ADSP WES and WGS data

237 The Alzheimer's Disease Sequencing Project (ADSP) is comprised of two Alzheimer's Disease (AD) genetics 238 consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimer's Disease Genetics 239 240 Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in 241 Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood 242 Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and 243 non-governmental organizations. The Discovery Phase analysis of sequence data is supported through 244 UF1AG047133 (to Drs. Schellenberg, Farrer, Pericak-Vance, Mayeux, and Haines); U01AG049505 to Dr. 245 Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijsman; and U01AG049508 to Dr. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate, 246 247 U01AG052410 to Dr. Pericak-Vance and U01 AG052409 to Drs. Seshadri and Fornage.

248 Sequencing for the Follow Up Study (FUS) is supported through U01AG057659 (to Drs. PericakVance, 249 Mayeux, and Vardarajan) and U01AG062943 (to Drs. Pericak-Vance and Mayeux). Data generation and 250 harmonization in the Follow-up Phase is supported by U54AG052427 (to Drs. Schellenberg and Wang). 251 The FUS Phase analysis of sequence data is supported through U01AG058589 (to Drs. Destefano, 252 Boerwinkle, De Jager, Fornage, Seshadri, and Wijsman), U01AG058654 (to Drs. Haines, Bush, Farrer, 253 Martin, and Pericak-Vance), U01AG058635 (to Dr. Goate), RF1AG058066 (to Drs. Haines, Pericak-Vance, 254 and Scott), RF1AG057519 (to Drs. Farrer and Jun), R01AG048927 (to Dr. Farrer), and RF1AG054074 (to 255 Drs. Pericak-Vance and Beecham).

256 The ADGC cohorts include: Adult Changes in Thought (ACT) (UO1 AG006781, UO1 HG004610, UO1 257 HG006375, U01 HG008657), the Alzheimer's Disease Centers (ADC) (P30 AG019610, P30 AG013846, P50 258 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 259 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 260 261 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 262 AG005136, P50 AG033514, P50 AG005681, and P50 AG047270), the Chicago Health and Aging Project 263 (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indianapolis Ibadan (R01 AG009956, P30 264 AG010133), the Memory and Aging Project (MAP) (R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990, 265 U01 AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinson's Disease controls 266 (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786, R01 267 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimer's Genetic 268 Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Cell Repository for 269 Alzheimer's Disease (NCRAD) (U24 AG21886), the National Institute on Aging Late Onset Alzheimer's 270 Disease Family Study (NIA- LOAD) (R01 AG041797), the Religious Orders Study (ROS) (P30 AG10161, R01 271 AG15819), the Texas Alzheimer's Research and Care Consortium (TARCC) (funded by the Darrell K Royal 272 Texas Alzheimer's Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01 273 AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer's Association), 274 the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1 AG054023), the University of 275 Washington Families (VA Research Merit Grant, NIA: P50AG005136, R01AG041797, NINDS: 276 R01NS069719), the Columbia University HispanicEstudio Familiar de Influencia Genetica de Alzheimer 277 (EFIGA) (RF1 AG015473), the University of Toronto (UT) (funded by Wellcome Trust, Medical Research 278 Council, Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). The 279 CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute (NHLBI) infrastructure

grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the neurology working group is supported by the
National Institute on Aging (NIA) R01 grant AG033193.

282 The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study 283 (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria (ASPS/PRODEM-Aus), the 284 Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus 285 Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is 286 funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical 287 University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project 1904), the EU Joint 288 Programme - Neurodegenerative Disease Research (JPND) in frame of the BRIDGET project (Austria, 289 Ministry of Science) and the Medical University of Graz and the Steiermärkische Krankenanstalten 290 Gesellschaft. PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No. 291 827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is carried out 292 as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, 293 HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, 294 HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01 295 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, 296 NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the 297 NHLBI. CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, 298 N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and 299 grants U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the National 300 Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, 301 R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts N01-HC-302 25195 and HHSN268201500001I. This study was also supported by additional grants from the NIA (R01s 303 AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP 304 305 grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's 306 Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4- 2007-201413 by the 307 European Commission under the programme "Quality of Life and Management of the Living Resources" 308 of 5th Framework Programme (no. QLG2-CT-2002- 01254). High-throughput analysis of the ERF data was 309 supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian 310 Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus 311 Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research

312 and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of 313 Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission 314 (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by the Netherlands 315 Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic 316 Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in 317 the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization 318 for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810. 319 All studies are grateful to their participants, faculty and staff. The content of these manuscripts is solely 320 the responsibility of the authors and does not necessarily represent the official views of the National 321 Institutes of Health or the U.S. Department of Health and Human Services.

322 The FUS cohorts include: the Alzheimer's Disease Centers (ADC) (P30 AG019610, P30 AG013846, P50 323 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 324 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 325 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 326 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 327 AG005136, P50 AG033514, P50 AG005681, and P50 AG047270), Alzheimer's Disease Neuroimaging 328 Initiative (ADNI) (U19AG024904), Amish Protective Variant Study (RF1AG058066), Cache County Study 329 (R01AG11380, R01AG031272, R01AG21136, RF1AG054052), Case Western Reserve University Brain Bank 330 (CWRUBB) (P50AG008012), Case Western Reserve University Rapid Decline (CWRURD) (RF1AG058267, 331 NU38CK000480), CubanAmerican Alzheimer's Disease Initiative (CuAADI) (3U01AG052410), Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) (5R37AG015473, RF1AG015473, R56AG051876), 332 333 Genetic and Environmental Risk Factors for Alzheimer Disease Among African Americans Study 334 (GenerAAtions) (2R01AG09029, R01AG025259, 2R01AG048927), Gwangju Alzheimer and Related Dementias Study (GARD) (U01AG062602), Hussman Institute for Human Genomics Brain Bank (HIHGBB) 335 336 (R01AG027944, Alzheimer's Association "Identification of Rare Variants in Alzheimer Disease"), Ibadan 337 Study of Aging (IBADAN) (5R01AG009956), Mexican Health and Aging Study (MHAS) (R01AG018016), 338 Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) (2R01AG09029, 339 R01AG025259, 2R01AG048927), Northern Manhattan Study (NOMAS) (R01NS29993), Peru Alzheimer's 340 Disease Initiative (PeADI) (RF1AG054074), Puerto Rican 1066 (PR1066) (Wellcome Trust 341 (GR066133/GR080002), European Research Council (340755)), Puerto Rican Alzheimer Disease Initiative 342 (PRADI) (RF1AG054074), Reasons for Geographic and Racial Differences in Stroke (REGARDS) 343 (U01NS041588), Research in African American Alzheimer Disease Initiative (REAAADI) (U01AG052410),

Rush Alzheimer's Disease Center (ROSMAP) (P30AG10161, R01AG15819, R01AG17919), University of
Miami Brain Endowment Bank (MBB), and University of Miami/Case Western/North Carolina A&T African
American (UM/CASE/NCAT) (U01AG052410, R01AG028786).

The four LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), The American Genome Center at the Uniformed Services University of the Health Sciences (U01AG057659), and the Washington University Genome Institute (U54HG003079).

351 Biological samples and associated phenotypic data used in primary data analyses were stored at Study 352 Investigators institutions, and at the National Cell Repository for Alzheimer's Disease (NCRAD, 353 U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and 354 secondary data analyses were provided by Study Investigators, the NIA funded Alzheimer's Disease 355 Centers (ADCs), and the National Alzheimer's Coordinating Center (NACC, U01AG016976) and the 356 National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, U24AG041689) 357 at the University of Pennsylvania, funded by NIA This research was supported in part by the Intramural Research Program of the National Institutes of health, National Library of Medicine. Contributors to the 358 359 Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and 360 other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental 361 organizations.

362 An up to date acknowledgment statement can be found on the ADSP363 site: https://www.niagads.org/adsp/content/acknowledgement-statement.

364 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative 365 (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award 366 number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of 367 Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, 368 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; 369 Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; 370 371 GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & 372 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso 373 Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals

Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Additional information to include in an acknowledgment statement can be found on the LONI site: https://adni.loni.usc.edu/wp-content/uploads/how to apply/ADNI Data Use Agreement.pdf.

383 The Alzheimer's Disease Genetics Consortium (ADGC) supported sample preparation, whole exome 384 sequencing and data processing through NIA grant U01AG032984. Sequencing data generation and 385 harmonization is supported by the Genome Center for Alzheimer's Disease, U54AG052427, and data 386 sharing is supported by NIAGADS, U24AG041689. Samples from the National Centralized Repository for 387 Alzheimer's Disease and Related Dementias (NCRAD), which receives government support under a 388 cooperative agreement grant (U24 AG021886) awarded by the National Institute on Aging (NIA), were 389 used in this study. We thank contributors who collected samples used in this study, as well as patients 390 and their families, whose help and participation made this work possible. NIH grants supported 391 enrollment and data collection for the individual studies including: GenerAAtions R01AG20688 (PI M. 392 Daniele Fallin, PhD); Miami/Duke R01 AG027944, R01 AG028786 (PI Margaret A. Pericak-Vance, PhD); NC 393 A&T P20 MD000546, R01 AG28786-01A1 (PI Goldie S. Byrd, PhD); Case Western (PI Jonathan L. Haines, 394 PhD); MIRAGE R01 AG009029 (PI Lindsay A. Farrer, PhD); ROS P30AG10161, R01AG15819, R01AG30146, 395 TGen (PI David A. Bennett, MD); MAP R01AG17917, R01AG15819, TGen (PI David A. Bennett, MD). The 396 NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded 397 ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI 398 James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 399 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn 400 Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, 401 PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI 402 Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 403 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI 404 Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), 405 P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI

Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez,
MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI
Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana,
MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD).

This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

We thank the contributors who collected samples used in this study, as well as patients and their families,
whose help and participation made this work possible. Members of the National Institute on Aging LateOnset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

This work was partially supported by grant funding from NIH R01 AG039700 and NIH P50 AG005136.
Subjects and samples used here were originally collected with grant funding from NIH U24 AG026395,
U24 AG021886, P50 AG008702, P01 AG007232, R37 AG015473, P30 AG028377, P50 AG05128, P50
AG16574, P30 AG010133, P50 AG005681, P01 AG003991, U01MH046281, U01 MH046290 and U01
MH046373. The funders had no role in study design, analysis or preparation of the manuscript. The
authors declare no competing interests.

428 This work was supported by the National Institutes of Health (R01 AG027944, R01 AG028786 to MAPV. 429 R01 AG019085 to JLH, P20 MD000546); a joint grant from the Alzheimer's Association (SG-14-312644) 430 and the Fidelity Biosciences Research Initiative to MAPV; the BrightFocus Foundation (A2011048 to 431 MAPV). NIA-LOAD Family-Based Study supported the collection of samples used in this study through NIH 432 grants U24 AG026395 and R01 AG041797 and the MIRAGE cohort was supported through the NIH grants 433 R01 AG025259 and R01 AG048927. We thank contributors, including the Alzheimer's disease Centers who 434 collected samples used in this study, as well as patients and their families, whose help and participation 435 made this work possible. Study design: HNC, BWK, JLH, MAPV; Sample collection: MLC, JMV, RMC, LAF, JLH, MAPV; Whole exome sequencing and Sanger sequencing: SR, PLW; Sequencing data analysis: HNC, 436

BWK, KLHN, SR, MAK, JRG, ERM, GWB, MAPV; Statistical analysis: BWK, KLHN, JMJ, MAPV; Preparation of
manuscript: HNC, BWK. The authors jointly discussed the experimental results throughout the duration
of the study. All authors read and approved the final manuscript.

Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP, PO1AG07232, R01AG037212, RF1AG054023) funded by the National Institute on Aging (NIA) and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. This manuscript has been reviewed by WHICAP investigators for scientific content and consistency of data interpretation with previous WHICAP Study publications. We acknowledge the WHICAP study participants and the WHICAP research and support staff for their contributions to this study.

This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991,
RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and
clinical characterization of research participants at Washington University were supported by NIH P50
AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made
possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry
at Washington University School of Medicine.

We thank the contributors who collected samples used in this study, as well as patients and their families,
whose help and participation made this work possible. Members of the National Institute on Aging LateOnset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

We thank the contributors who collected samples used in this study, as well as patients and their families,
whose help and participation made this work possible. Members of the National Institute on Aging Late-

Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

471 Mayo RNAseq Study-Study data were provided by the following sources: The Mayo Clinic Alzheimer's 472 Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, 473 Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease 474 Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA 475 grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, 476 R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and 477 support from Mayo Foundation. Study data includes samples collected through the Sun Health Research 478 Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is 479 supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain 480 and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 481 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 482 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 483 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox 484 Foundation for Parkinson's Research

ROSMAP- We are grateful to the participants in the Religious Order Study, the Memory and Aging Project.
This work is supported by the US National Institutes of Health [U01 AG046152, R01 AG043617, R01
AG042210, R01 AG036042, R01 AG036836, R01 AG032990, R01 AG18023, RC2 AG036547, P50 AG016574,
U01 ES017155, KL2 RR024151, K25 AG041906-01, R01 AG30146, P30 AG10161, R01 AG17917, R01
AG15819, K08 AG034290, P30 AG10161 and R01 AG11101.

Mount Sinai Brain Bank (MSBB)- This work was supported by the grants R01AG046170, RF1AG054014,
 RF1AG057440 and R01AG057907 from the NIH/National Institute on Aging (NIA). R01AG046170 is a
 component of the AMP-AD Target Discovery and Preclinical Validation Project. Brain tissue collection and
 characterization was supported by NIH HHSN271201300031C.

This study was supported by the National Institute on Aging (NIA) grants AG030653, AG041718, AG064877
and P30-AG066468.

We would like to thank study participants, their families, and the sample collectors for their invaluable
contributions. This research was supported in part by the National Institute on Aging grant U01AG049508
(PI Alison M. Goate). This research was supported in part by Genentech, Inc. (PI Alison M. Goate, Robert
R. Graham).

500 The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by these NIA-501 funded ADCs: P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI 502 Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), 503 P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P30 504 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David 505 Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 506 AG005131 (PI Douglas Galasko, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John 507 Trojanowski, MD, PhD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), 508 P50 AG005136 (PI Thomas Grabowski, MD), P50 AG005681 (PI John Morris, MD), P30 AG028377 (Kathleen 509 Welsh-Bohmer, PhD), and P50 AG008671 (PI Henry Paulson, MD, PhD).

510 Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government

511 support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging

512 (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as

513 patients and their families, whose help and participation made this work possible.

- The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01AG032984 and RC2AG036528.
- 516 We acknowledge the generous contributions of the Cache County Memory Study participants. Sequencing
- 517 for this study was funded by RF1AG054052 (PI: John S.K. Kauwe)

518 Acknowledgments for the use of GWAS data distributed by NIAGADS

519 The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is supported by a collaborative 520 agreement from the National Institute on Aging, U24AG041689.

- 521 NG00047: The NIA supported this work through grants U01-AG032984, RC2-AG036528, U01-AG016976 522 (Dr Kukull); U24 AG026395, U24 AG026390, R01AG037212, R37 AG015473 (Dr Mayeux); K23AG034550
- 523 (Dr Reitz); U24-AG021886 (Dr Foroud); R01AG009956, RC2 AG036650 (Dr Hall); UO1 AG06781, UO1
- 524 HG004610 (Dr Larson); R01 AG009029 (Dr Farrer); 5R01AG20688 (Dr Fallin); P50 AG005133, AG030653

525 (Dr Kamboh); R01 AG019085 (Dr Haines); R01 AG1101, R01 AG030146, RC2 AG036650 (Dr Evans); 526 P30AG10161, R01AG15819, R01AG30146, R01AG17917, R01AG15819 (Dr Bennett); R01AG028786 (Dr 527 Manly); R01AG22018, P30AG10161 (Dr Barnes); P50AG16574 (Dr Ertekin-Taner, Dr Graff-Radford), R01 528 AG032990 (Dr Ertekin-Taner), KL2 RR024151 (Dr Ertekin-Taner); R01 AG027944, R01 AG028786 (Dr 529 Pericak-Vance); P20 MD000546, R01 AG28786-01A1 (Dr Byrd); AG005138 (Dr Buxbaum); P50 AG05681, 530 P01 AG03991, P01 AG026276 (Dr Goate); and P30AG019610, P30AG13846, U01-AG10483, R01CA129769, R01MH080295, R01AG017173, R01AG025259, R01AG33193, P50AG008702, P30AG028377, AG05128, 531 AG025688, P30AG10133, P50AG005146, P50AG005134, P01AG002219, P30AG08051, M01RR00096, 532 533 UL1RR029893, P30AG013854, P30AG008017, R01AG026916, R01AG019085, P50AG016582, 534 UL1RR02777, R01AG031581, P30AG010129, P50AG016573, P50AG016575, P50AG016576, 535 P50AG016577, P50AG016570, P50AG005131, P50AG023501, P50AG019724, P30AG028383, 536 P50AG008671, P30AG010124, P50AG005142, P30AG012300, AG010491, AG027944, AG021547, 537 AG019757, P50AG005136 (Alzheimer Disease GeneticsConsortium [ADGC]). We thank Creighton Phelps, 538 Stephen Synder, and Marilyn Miller from the NIA, who are ex-officio members of the ADGC. Support was 539 also provided by the Alzheimer's Association (IIRG-08-89720 [Dr Farrer] and IIRG-05-14147 [Dr Pericak-540 Vance]), National Institute of Neurological Disorders and Stroke grant NS39764, National Institute of 541 Mental Health grant MH60451, GlaxoSmithKline, and the Office of Research and Development, 542 Biomedical Laboratory Research Program, US Department of Veterans Affairs Administration. For the 543 ADGC, biological samples and associated phenotypic data used in primary data analyses were stored at 544 principal investigators' institutions and at the National Cell Repository for Alzheimer's Disease (NCRAD) at 545 Indiana University, funded by the NIA. Associated phenotypic data used in secondary data analyses were 546 stored at the National Alzheimer's Coordinating Center and at the NIA Alzheimer's Disease Data Storage 547 Site at the University of Pennsylvania, funded by the NIA. Contributors to the genetic analysis data 548 included principal investigators on projects ndividually funded by the NIA, other NIH institutes, or private 549 entities.

550 Acknowledgments for other GWAS and phenotype data

551 NACC

The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIAfunded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG06242801 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD),
P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI

556 Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 557 558 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, 559 MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 560 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce 561 Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 562 563 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 564 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, 565 566 MD, PhD).

567 MARS & LATC

We thank all Minority Aging Research Study and Latino Core participants and the Rush Alzheimer's Disease
Center staff. This database was funded by the NIH/NIA grants R01AG22018 (MARS) and P30AG 072975
(ADC).

571 GenADA

572 The genotypic and associated phenotypic data used in the study "Multi-Site Collaborative Study for 573 Genotype-Phenotype Associations in Alzheimer's Disease (GenADA)" were provided by the 574 GlaxoSmithKline, R&D Limited.

575 **ROSMAP**

ROSMAP study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical
Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819,
R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public
Health, and the Translational Genomics Research Institute.

580 AddNeuroMed

The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy

586 Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics 587 leads are Richard Dobson (London) and Stephen Newhouse (London).

588 ADNI

589 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative 590 (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award 591 number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie. 592 593 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica. Inc.; Biogen; 594 Bristol-Myers Squibb Company; CereSpir. Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals. Inc.; Eli Lilly and 595 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech. Inc.; Fujirebio; 596 GE HealtControlsare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development. LLC.; 597 Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.; 598 Meso Scale Diagnostics. LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals 599 Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition 600 Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites 601 in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of 602 Health. The grantee organization is the Northern California Institute for Research and Education, and the 603 study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern 604 California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern 605 California.

606 NCRAD

Biological samples used in this study were stored at study investigators' institutions and at the National
Cell Repository for Alzheimer's Disease (NCRAD) at Indiana University, which receives government support
under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA).
We thank contributors who collected samples used in this study, as well as patients and their families,
whose help and participation made this work possible.

612 UK Biobank

613 UK Biobank data were analyzed under Application Number 45420.

614

615 VA Million Veteran Program: Core Acknowledgement

616 MVP Program Office

- 617 Sumitra Muralidhar, Ph.D., Program Director
- 618 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
- 619 Jennifer Moser, Ph.D., Associate Director, Scientific Programs
- 620 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
- 621 Jennifer E. Deen, B.S., Associate Director, Cohort & Public Relations
- 622 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420

623 MVP Executive Committee

- 624 Co-Chair: Philip S. Tsao, Ph.D.
- 625 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
- 626 Co-Chair: Sumitra Muralidhar, Ph.D.
- 627 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
- 628 J. Michael Gaziano, M.D., M.P.H.
- 629 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
- 630 Elizabeth Hauser, Ph.D.
- 631 Durham VA Medical Center, 508 Fulton Street, Durham, NC 27705
- 632 Amy Kilbourne, Ph.D., M.P.H.
- 633 VA HSR&D, 2215 Fuller Road, Ann Arbor, MI 48105
- 634 Michael Matheny, M.D., M.S., M.P.H.
- VA Tennessee Valley Healthcare System, 1310 24th Ave. South, Nashville, TN 37212
 Dave Oslin, M.D.
- 637 Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104
- 638 MVP Co-Principal Investigators
- 639 J. Michael Gaziano, M.D., M.P.H.
- 640 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
- 641 Philip S. Tsao, Ph.D.
- 642 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304

643 MVP Core Operations

- 644 Jessica V. Brewer, M.P.H., Director, Cohort Operations
- 645 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
 646 Mary T. Brophy M.D., M.P.H., Director, Biorepository
- 647 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
- VA BOSION HEAlthcare System, 150 S. Huntington Avenue, Bosion, MA O.
- 648 Kelly Cho, M.P.H, Ph.D., Director, MVP Phenomics
- 649 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
- 650 Lori Churby, B.S., Director, Regulatory Affairs
- VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
- Scott L. DuVall, Ph.D., Director, VA Informatics and Computing Infrastructure (VINCI)
- 653 VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148
- 654 Saiju Pyarajan Ph.D., Director, Data and Computational Sciences

655	VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130	
656	 Luis E. Selva, Ph.D., Director, MVP Biorepository Coordination 	
657	VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130	
658	 Shahpoor (Alex) Shayan, M.S., Director, MVP PRE Informatics 	
659	VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130	
660	- Stacey B. Whitbourne, Ph.D., Director, MVP Cohort Development and Management	
661	VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130	
662	- MVP Coordinating Centers	
663	 MVP Coordinating Center, Boston - J. Michael Gaziano, M.D., M.P.H. 	
664	VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130	
665	 MVP Coordinating Center, Palo Alto – Philip S. Tsao, Ph.D. 	
666	VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304	
667	 MVP Information Center, Canandaigua – Brady Stephens, M.S. 	
668	Canandaigua VA Medical Center, 400 Fort Hill Avenue, Canandaigua, NY 14424	
669	\circ Cooperative Studies Program Clinical Research Pharmacy Coordinating	Center,
670	Albuquerque – Todd Connor, Pharm.D.; Dean P. Argyres, B.S., M.S.	
671	New Mexico VA Health Care System, 1501 San Pedro Drive SE, Albuquerque, NM 87108	
672	MVP Publications and Presentations Committee	
672	Conclusion The existencies of American MAD and a	
6/3	- Co-Chair: Themistocies L. Assimes, IVI.D., Ph. D	
674	VA Paio Alto Health Care System, 3801 Miranda Avenue, Paio Alto, CA 94304	
675	- Co-Chair: Adriana Hung, M.D.; M.P.H	
0/0 677	VA Tennessee Valley HealthCare System, 1310 24 th Ave. South, Nashville, TN 37212	
677	- CO-Chair: Henry Kranzier, IVI.D. Dhiladalahia VA Madical Conter, 2000 Weadland Avenue, Dhiladalahia, DA 10104	
078	Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104	
679	MVP Local Site Investigators	
680	- Samuel Aguayo, M.D., Phoenix VA Health Care System	
681	650 E. Indian School Road, Phoenix, AZ 85012	
682	 Sunil Ahuja, M.D., South Texas Veterans Health Care System 	
683	7400 Merton Minter Boulevard, San Antonio, TX 78229	
684	 Kathrina Alexander, M.D., Veterans Health Care System of the Ozarks 	
685	1100 North College Avenue, Fayetteville, AR 72703	
686	 Xiao M. Androulakis, M.D., Columbia VA Health Care System 	
687	6439 Garners Ferry Road, Columbia, SC 29209	
688	- Prakash Balasubramanian, M.D., William S. Middleton Memorial Veterans Hospital	
689	2500 Overlook Terrace, Madison, WI 53705	
690	 Zuhair Ballas, M.D., Iowa City VA Health Care System 	
691	601 Highway 6 West, Iowa City, IA 52246-2208	
692	- Elizabeth S. Bast, M.D., M.P.H., Miami VA Health Care System	
693	1201 NW 16th Street, 11 GRC, Miami FL 33125	
694	- Jean Beckham, Ph.D., Durham VA Medical Center	
695	508 Fulton Street, Durham, NC 27705	
696	- Sujata Bhushan, M.D., VA North Texas Health Care System	
697	4500 S. Lancaster Road, Dallas, TX 75216	
698	 Edward Boyko, M.D., VA Puget Sound Health Care System 	

699	1660 S. Columbian Way, Seattle, WA 98108-1597
700	- David Cohen, M.D., Portland VA Medical Center
701	3710 SW U.S. Veterans Hospital Road, Portland, OR 97239
702	- Louis Dellitalia, M.D., Birmingham VA Medical Center
703	700 S. 19th Street, Birmingham AL 35233
704	- Gerald Wayne Dryden, Jr., M.D., Ph.D., Louisville VA Medical Center
705	800 Zorn Avenue, Louisville, KY 40206
706	- L. Christine Faulk, M.D., Robert J. Dole VA Medical Center
707	5500 East Kellogg Drive, Wichita, KS 67218-1607
708	 Joseph Fayad, M.D., VA Southern Nevada Healthcare System
709	6900 North Pecos Road, North Las Vegas, NV 89086
710	 Daryl Fujii, Ph.D., VA Pacific Islands Health Care System
711	459 Patterson Rd, Honolulu, HI 96819
712	- Saib Gappy, M.D., John D. Dingell VA Medical Center
713	4646 John R Street, Detroit, MI 48201
714	 Frank Gesek, Ph.D., White River Junction VA Medical Center
715	163 Veterans Drive, White River Junction, VT 05009
716	 Michael Godschalk, M.D., Richmond VA Medical Center
717	1201 Broad Rock Blvd., Richmond, VA 23249
718	 Jennifer Greco, M.D., Sioux Falls VA Health Care System
719	2501 W 22nd Street, Sioux Falls, SD 57105
720	 Todd W. Gress, M.D., Ph.D., Hershel "Woody" Williams VA Medical Center
721	1540 Spring Valley Drive, Huntington, WV 25704
722	 Samir Gupta, M.D., M.S.C.S., VA San Diego Healthcare System
723	3350 La Jolla Village Drive, San Diego, CA 92161
724	 Salvador Gutierrez, M.D., Edward Hines, Jr. VA Medical Center
725	5000 South 5th Avenue, Hines, IL 60141
726	 Mark Hamner, M.D., Ralph H. Johnson VA Medical Center
727	109 Bee Street, Mental Health Research, Charleston, SC 29401
728	- John Harley, M.D., Ph.D., Cincinnati VA Medical Center
729	3200 Vine Street, Cincinnati, OH 45220
730	- Daniel J. Hogan, M.D., Bay Pines VA Healthcare System
731	10,000 Bay Pines Blvd Bay Pines, FL 33744
732	- Adriana Hung, M.D., M.P.H., VA Tennessee Valley Healthcare System
/33	1310 24th Avenue, South Nashville, TN 37212
/34	- Robin Hurley, M.D., W.G. (Bill) Hefner VA Medical Center
/35	1601 Brenner Ave, Salisbury, NC 28144
/36	- Pran Iruvanti, D.O., Ph.D., Hampton VA Medical Center
/3/	100 Emancipation Drive, Hampton, VA 23667
/38	- Frank Jacono, M.D., VA Northeast Ohio Healthcare System
739	10/01 East Boulevard, Cleveland, OH 44106
740	- Darshana Jhala, M.D., Philadelphia VA Medical Center
741	3900 Woodland Avenue, Philadelphia, PA 19104
742	- Seema Joshi, M.D., F.A.C.P., ABUIM; VA Eastern Kansas Health Care System
/43 744	4101 S 4th Street Tramcway, LeavenWorth, KS 66048
744	- Scott Kiniay, Wi.B.B.S., Ph.D., VA Boston Healthcare System
745	150 S. HUNTINGTON AVENUE, BOSTON, MA U2130
/46	- IVIICHAEI LANDRY, Ph.D., Southeast Louisiana Veterans Health Care System

747	2400 Canal Street, New Orleans, LA 70119
748	 Peter Liang, M.D., M.P.H., VA New York Harbor Healthcare System
749	423 East 23rd Street, New York, NY 10010
750	- Suthat Liangpunsakul, M.D., M.P.H., Richard Roudebush VA Medical Center
751	1481 West 10th Street, Indianapolis, IN 46202
752	 Jack Lichy, M.D., Ph.D., Washington DC VA Medical Center
753	50 Irving St, Washington, D. C. 20422
754	- Tze Shien Lo, M.D., Fargo VA Health Care System
755	2101 N. Elm, Fargo, ND 58102
756	- C. Scott Mahan, M.D., Charles George VA Medical Center
757	1100 Tunnel Road, Asheville, NC 28805
758	- Ronnie Marrache, M.D., VA Maine Healthcare System Center, Augusta, ME 04330
759	- Stephen Mastorides, M.D., James A. Haley Veterans' Hospital
760	13000 Bruce B. Downs Blvd, Tampa, FL 33612
761	- Kristin Mattocks, Ph.D., M.P.H., Central Western Massachusetts Healthcare System
762	421 North Main Street, Leeds, MA 01053
763	- Paul Meyer, M.D., Ph.D., Southern Arizona VA Health Care System
764	3601 S 6th Avenue, Tucson, AZ 85723
765	- Jonathan Moorman, M.D., Ph.D., James H. Quillen VA Medical Center
766	Corner of Lamont & Veterans Way, Mountain Home, TN 37684
767	- Providencia Morales, R.N., Northern Arizona VA Health Care System
768	500 Highway 89 North, Prescott, AZ 86313
769	- Timothy Morgan, M.D., VA Long Beach Healthcare System
770	5901 East 7th Street Long Beach, CA 90822
771	- Maureen Murdoch, M.D., M.P.H., Minneapolis VA Health Care System
772	One Veterans Drive, Minneapolis, MN 55417
773	- Eknath Naik, M.D., Ph.D., West Palm Beach VA Medical Center,
774	7305 North Military Trail, West Palm Beach, FL 33410-6400
775	- James Norton, Ph.D., VA Health Care Upstate New York
776	113 Holland Avenue, Albany, NY 12208
777	- Olaoluwa Okusaga, M.D., Michael E. DeBakey VA Medical Center
778	2002 Holcombe Blvd, Houston, TX 77030
779	- Michael K. Ong, M.D., VA Greater Los Angeles Health Care System
780	11301 Wilshire Blvd, Los Angeles, CA 90073
781	- Kris Ann Oursler, M.D., Salem VA Medical Center
782	1970 Roanoke Blvd, Salem, VA 24153
783	- Ismene Petrakis, M.D., VA Connecticut Healthcare System
784	950 Campbell Avenue, West Haven, CT 06516
785	- Samuel Poon, M.D., Manchester VA Medical Center
786	718 Smyth Road, Manchester, NH 03104
787	- Amneet S. Rai, Pharm.D., VA Sierra Nevada Health Care System
788	975 Kirman Avenue, Reno, NV 89502
789	- Michael Rauchman, M.D., St. Louis VA Health Care System
790	915 North Grand Blvd, St. Louis, MO 63106
791	- Richard Servatius, Ph.D., Syracuse VA Medical Center
792	800 Irving Avenue, Syracuse, NY 13210
793	- Satish Sharma, M.D., Providence VA Medical Center
794	830 Chalkstone Avenue, Providence, RI 02908

795 River Smith, Ph.D., Eastern Oklahoma VA Health Care System -796 1011 Honor Heights Drive, Muskogee, OK 74401 797 Peruvemba Sriram, M.D., N. FL/S. GA Veterans Health System 798 1601 SW Archer Road, Gainesville, FL 32608 799 Patrick Strollo, Jr., M.D., VA Pittsburgh Health Care System 800 University Drive, Pittsburgh, PA 15240 801 Neeraj Tandon, M.D., Overton Brooks VA Medical Center 802 510 East Stoner Ave, Shreveport, LA 71101 803 Philip Tsao, Ph.D., VA Palo Alto Health Care System 804 3801 Miranda Avenue, Palo Alto, CA 94304-1290 805 -Gerardo Villareal, M.D., New Mexico VA Health Care System 806 1501 San Pedro Drive, S.E. Albuquerque, NM 87108 807 Jessica Walsh, M.D., VA Salt Lake City Health Care System 808 500 Foothill Drive, Salt Lake City, UT 84148 809 John Wells, Ph.D., Edith Nourse Rogers Memorial Veterans Hospital -810 200 Springs Road, Bedford, MA 01730 Jeffrey Whittle, M.D., M.P.H., Clement J. Zablocki VA Medical Center 811 812 5000 West National Avenue, Milwaukee, WI 53295 Mary Whooley, M.D., San Francisco VA Health Care System 813 4150 Clement Street, San Francisco, CA 94121 814 815 Peter Wilson, M.D., Atlanta VA Medical Center 1670 Clairmont Road, Decatur, GA 30033 816 817 Junzhe Xu, M.D., VA Western New York Healthcare System 818 3495 Bailey Avenue, Buffalo, NY 14215-1199 819 Shing Shing Yeh, Ph.D., M.D., Northport VA Medical Center 820 79 Middleville Road, Northport, NY 11768 821 Andrew W. Yen, M.D., VA Northern California Health Care System 822 10535 Hospital Way, Mather, CA 95655

823 References

824	1.	Sun L, Wang Z, Lu T, Manolio TA, Paterson AD. eXclusionarY: 10 years later, where
825		are the sex chromosomes in GWASs? The American Journal of Human Genetics.
826		2023;110(6):903-912. doi:10.1016/j.ajhg.2023.04.009
827	2.	Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's and
828		Dementia. 2023;19(4):1598-1695. doi:10.1002/alz.13016
829	3.	NIAGADS. NG00067 – ADSP Umbrella. Published 2021. Accessed November 1,
830		2021. https://dss.niagads.org/datasets/ng00067/
831	4.	Kuzma A, Valladares O, Cweibel R, et al. NIAGADS: The NIA Genetics of Alzheimer's
832		Disease Data Storage Site. Alzheimer's & Dementia. 2016;12(11):1200-1203.
833		doi:10.1016/j.jalz.2016.08.018
834	5.	Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
835		phenotyping and genomic data. Nature. 2018;562:203-209. doi:10.1038/s41586-
836		018-0579-z
837	6.	Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-
838		phenotyped isolated population. <i>Nature</i> . 2023;613(7944):508-518.
839		doi:10.1038/S41586-022-05473-8
840	7.	Sherva R, Zhang R, Sahelijo N, et al. African ancestry GWAS of dementia in a large
841		military cohort identifies significant risk loci. Mol Psychiatry. 2023;28(3):1293-
842		1302. doi:10.1038/s41380-022-01890-3
843	8.	Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality
844		Control in the Million Veteran Program. The American Journal of Human Genetics.
845		2020;106(4):535-548. doi:10.1016/J.AJHG.2020.03.004
846	9.	Le Guen Y, Napolioni V, Belloy ME, et al. Common X-Chromosome Variants Are
847		Associated with Parkinson Disease Risk. Ann Neurol. 2021;90(1):22-34.
848		doi:10.1002/ana.26051
849	10.	Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new
850		loci and functional pathways influencing Alzheimer's disease risk. Nat Genet.
851		2019;51(3):404-413. doi:10.1038/s41588-018-0311-9
852	11.	Loh P ru, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
853		biobank-scale datasets. Nat Genet. 2018;50:906-908. doi:10.1038/s41588-018-
854		0144-6

855	12.	Sidorenko J, Kassam I, Kemper KE, et al. The effect of X-linked dosage
856		compensation on complex trait variation. Nat Commun. 2019;10(1).
857		doi:10.1038/s41467-019-10598-y
858	13.	Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian Test for Colocalisation
859		between Pairs of Genetic Association Studies Using Summary Statistics. PLoS
860		Genet. 2014;10(5):1-15. doi:10.1371/journal.pgen.1004383
861	14.	Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate
862		AM. The complex genetic architecture of Alzheimer's disease: novel insights and
863		future directions. EBioMedicine. 2023;90. doi:10.1016/J.EBIOM.2023.104511
864	15.	Stopschinski BE, Holmes BB, Miller GM, et al. Specific glycosaminoglycan chain
865		length and sulfation patterns are required for cell uptake of tau versus alfa-
866		synuclein and beta-amyloid aggregates. Journal of Biological Chemistry.
867		2018;293(27):10826-10840. doi:10.1074/jbc.RA117.000378
868	16.	Pohlkamp T, Xian X, Wong CH, et al. NHE6 depletion corrects ApoE4-mediated
869		synaptic impairments and reduces Amyloid plaque load. Elife. 2021;10.
870		doi:10.7554/eLife.72034
871		
872		
873		



874

Figure 1. X chromosome-wide association study of Alzheimer's disease. A) Overview of study design and
sample sizes. To increase specificity to AD (rather than ADD), the XWAS meta-analysis was intersected to
variants with association results in ADGC (which used only clinically confirmed cases and controls). B)
Manhattan plot for the XWAS meta-analysis. The dotted line indicates X-chromosome-wide significance
(P-value<1e-5) and full line indicates genome-wide significance (P-value<5e-8). Lead variants for
independent loci are annotated with their nearest protein-coding gene (Gencode v42).

881 Table 1. X chromosome-wide association study of Alzheimer's disease: Associated lead variants. The Direction column indicates the association 882 effect direction across meta-analyzed cohorts following the order of ADGC, ADSP, UKB, FinnGen, MVP-1 (using health registry status), and MVP-2 883 (using proxy status). A question mark indicates the variant was not available in the respective cohort. Variants are annotated using dbSNP153. Association signals passing genome-wide significance are bolded. 884

	Nearest protein									
Lead variant	coding gene	Consequence	ВР	EA	OA	No. Subjects	EAF	OR [95%-CI] ‡	Р	Direction
rs150798997	NLGN4X	intergenic	5,733,126	А	Т	1,145,553	0.32%	0.644 [0.537, 0.772]	2.08E-06	- ?
rs12852495	MID1	intronic	10,458,864	Т	С	1,151,353	0.26%	1.538 [1.276, 1.855]	6.60E-06	+++++
rs2142791	SLC9A7	intronic	46,691,127	С	Α	1,152,185	46.12%	1.054 [1.035, 1.075]	3.78E-08	+++++
rs209215	ZNF280C	intronic	130,251,839	Т	С	1,145,797	39.90%	1.048 [1.028, 1.069]	2.70E-06	+ ? + + + +
rs5975709 +	MAP7D3	intronic	136,256,153	С	Т	1,145,797	43.25%	0.953 [0.935, 0.972]	1.02E-06	- ?
rs5930938 +	ADGRG4	intronic	136,380,525	Т	С	733,616	32.62%	0.943 [0.921, 0.965]	7.55E-07	- ? - ?
rs146964414	MTM1	intronic	150,608,170	Т	С	1,152,184	8.23%	1.096 [1.060, 1.133]	8.10E-08	+ - + + + +

885

[‡] The odds ratios are reported with regard to a single active allele. In women, due to random XCI, the relative risk conferred would be half that 886 reported here. 887

888 + Rs5975709 was the lead variant in its respective locus, but it had no association results in ADSP and FinnGen. The second most significant variant in this locus, rs5930938, did have association results in FinnGen and was therefore additionally listed to provide additional insight. 889

Abbreviations: OR, odds ratio; CI, confidence interval; EA, effect allele; OA, other allele; EAF, effect allele frequency; BP, base pair; No., number. 890

Table 2. Genetic colocalization with quantitative trait locus data. Colocalization was evaluated for genes in each AD associated locus using a 2Mb window centered on the lead variant. Evidence for colocalization was considered at colocalization posterior probability (PP4)>0.7 (bolded). The table presents PP4 results and is restricted to genes and datasets/tissues where at least one colocalization reached PP4>0.7. As such, the table is partitioned into 4 common variant loci that showed colocalization support. Bolded entries with an asterisk (*) indicate the lead variant was also a significant QTL in the respective data/tissue. Missing entries indicate that no QTL data were available. The total number of times a gene was prioritized (PP4>0.7) is summarized to help identify the most likely causal gene per locus (blue bolded genes and numbers). Overlapping datasets were considered as those where subjects partially or fully overlapped (non-overlapping datasets are separated by dashed lines).

			SLC9A7								ZNF	280C		ADGRG4					MTM1	
Dataset	Tissue	QTL	ENSG00000286306	KRBOX4	CHST7	SLC9A7	RP2	JADE3	UBA1	ELK1	ELF4	AIFM1	ZNF280C	RBMX2	EHL1	MAP7D3	BRS3	HTATSF1	AL683813.2	MTMR1
Wingo et al. 2023 (AD Knowledge Portal) Brain - Dorsolateral prefrontal cortex pQTL		pQTL				0.56	0.89*		0.05			0.02			0.12	0.05		0.03		0.01
Wingo et al. 2023 (AD Knowledge Port	al) Brain - Dorsolateral prefrontal cortex	eQTL		0.77*	0.95*	0.56	0.04	0.70*	0.04	0.00		0.16	0.45	0.00	0.78*	0.93*		0.05		0.05
CommonMind (eQTL Catalogue)	Brain - Dorsolateral prefrontal cortex	eQTL	0.88	0.04	0.92*	0.86*	0.07	0.07	0.93*	0.04	0.05	0.12	0.09	0.29	0.13	0.92*	0.04	0.03		0.16
GTEx	Brain - (9 brain areas)	eQTL		0.74	0.86*	0.64	0.13	0.51	0.12	0.33	0.11	0.56	0.77*	0.07	0.10	0.77*	0.04	0.04	0.07	0.88
GTEx	Wholeblood	eQTL		0.23	0.20	0.39	0.03	0.06	0.07	0.03	0.02	0.19	0.05	0.02	0.02	0.92*		0.01	0.02	0.01
GTEx	Other (20 tissues not brain or blood)	eQTL		0.92	0.71	0.98*	0.14	0.76	0.10	0.16	0.78*	0.78*	0.92*	0.77	0.13	0.89*	0.73	0.87*	0.77	0.79
Fairfax et al. 2014 (eQTL Catalogue)	Monocytes (4 conditions)	eQTL		0.10	0.27	0.93*	0.50	0.10	0.13	0.86	0.01	0.73	0.19	0.04	0.85	0.13	0.04	0.07		0.18
CEDAR (eQTL Catalogue)	Monocytes	eQTL		0.05	0.15	0.93*	0.05	0.43	0.12	0.08	0.06	0.78*	0.04	0.05	0.29	0.08	0.04	0.06		0.11
No. times prioritized across datasets & tissues				4	10	12	1	2	1	1	1	6	17	1	2	10	1	2	1	2
No. times prioritized in non-overlapping datasets				2	3	4	1	2	1	1	1	3	1	1	2	3	1	1	1	1

898

899 *Abbreviations: QTL, quantitative trait locus; eQTL, expression quantitative trait locus; pQTL, protein quantitative trait locus; No., number.*